Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
Abstract Purpose of Review To discuss novel targeted therapies under investigation for
treatment of myelodysplastic neoplasms (MDS). Recent Findings Over the last few years …
treatment of myelodysplastic neoplasms (MDS). Recent Findings Over the last few years …
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
P Pophali, SR Desai, A Shastri - … hematologic malignancy reports - pubmed.ncbi.nlm.nih.gov
Purpose of review To discuss novel targeted therapies under investigation for treatment of
myelodysplastic neoplasms (MDS). Recent findings Over the last few years, results of phase …
myelodysplastic neoplasms (MDS). Recent findings Over the last few years, results of phase …
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
P Pophali, SR Desai, A Shastri - Current Hematologic …, 2023 - einstein.elsevierpure.com
Abstract Purpose of Review: To discuss novel targeted therapies under investigation for
treatment of myelodysplastic neoplasms (MDS). Recent Findings: Over the last few years …
treatment of myelodysplastic neoplasms (MDS). Recent Findings: Over the last few years …
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
P Pophali, SR Desai, A Shastri - Current Hematologic Malignancy …, 2023 - europepmc.org
Over the last few years, results of phase 3 trials assessing novel therapies for high-risk MDS
have been largely disappointing. Pevonedistat (NEDD-8 inhibitor) and APR-246 (TP53 …
have been largely disappointing. Pevonedistat (NEDD-8 inhibitor) and APR-246 (TP53 …